RAS has become a hot target for #cancer research, but these proteins are hard to hit with small molecule drugs. They don't have sites where small molecules can bind. $RVMD says its proprietary tech creates "druggable pockets" that drugs can bind to.
-
-
-
It got its start in 2015, spinning out of VC firm
@ThirdRockV.#Cancer was not Revolution's initial target, but that focus developed as the University of Illinois technology that formed the basis of the#startup led it to a way to drug RAS. https://xconomy.com/san-francisco/2015/02/04/third-rocks-new-revolution-looks-to-squeeze-more-drugs-from-nature/ …$RVMDPrikaži ovu nit -
Revolution is the company that acquired Warp Drive Bio in 2018, biotech that was also developing RAS
#cancer drugs. https://xconomy.com/san-francisco/2018/10/16/warp-drives-odyssey-ends-with-a-buyout-to-revolution-not-sanofi/ …$RVMDPrikaži ovu nit -
Details about that deal and more are in Revolution Medicines' S-1 filing: https://www.sec.gov/Archives/edgar/data/1628171/000119312520010145/d799036ds1.htm#toc799036_17 …
$RVMDPrikaži ovu nit
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.